Low-level fluoroquinolone resistance among Campylobacter jejuni isolates in Australia. 2006

Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
OzFoodNet, Queensland Health, Archerfield, Queensland, Australia. leanne.unicomb@anu.edu.au

BACKGROUND Ciprofloxacin-resistant Campylobacter jejuni isolates obtained from infected patients in Australia have not been detected in studies of isolates from specific geographic areas. The Australian government has prohibited the use of fluoroquinolone in food-producing animals. To assess the impact of this policy, we have examined the antimicrobial susceptibility of isolates from 5 Australian states. METHODS We conducted a period-prevalence survey of the susceptibility of C. jejuni isolates to 10 antimicrobial agents. C. jejuni isolates obtained from 585 patients from 5 Australian states (Queensland, South Australia, Tasmania, Victoria, and Western Australia) were identified by means of notifiable disease databases and were systematically selected from September 2001 to August 2002. RESULTS Among locally acquired infections, only 2% of isolates (range, 0%-8% in different states) were resistant to ciprofloxacin. The locally acquired isolates also exhibited resistance to sulfisoxazole (55%), ampicillin (46%), roxithromycin (38%), tetracycline (7%), nalidixic acid (6%), chloramphenicol (3%), erythromycin (3%), gentamicin (2%), and kanamycin (0.2%). Treatment with antimicrobial agents in the 4 weeks before onset was not associated with ciprofloxacin resistance. CONCLUSIONS The very low level of ciprofloxacin resistance in C. jejuni isolates likely reflects the success of Australia's policy of restricting use of fluoroquinolones in food-producing animals.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D002169 Campylobacter Infections Infections with bacteria of the genus CAMPYLOBACTER. Campylobacter Infection,Campylobacteriosis,Infections, Campylobacter,Campylobacterioses,Infection, Campylobacter
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001315 Australia The smallest continent and an independent country, comprising six states and two territories. Its capital is Canberra. Canton and Enderbury Islands,Christmas Island,Christmas Island (Australia)
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016123 Campylobacter jejuni A species of bacteria that resemble small tightly coiled spirals. Its organisms are known to cause abortion in sheep and fever and enteritis in man and may be associated with enteric diseases of calves, lambs, and other animals. Campylobacter fetus subsp. jejuni,Vibrio hepaticus,Vibrio jejuni
D018579 Patient Selection Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols. Patient Recruitment,Research Subject Recruitment,Selection Criteria,Research Subject Selection,Selection for Treatment,Selection of Research Volunteers,Selection of Subjects,Criteria, Selection,Recruitment, Patient,Recruitment, Research Subject,Recruitments, Research Subject,Research Subject Recruitments,Research Subject Selections,Research Volunteers Selection,Research Volunteers Selections,Selection for Treatments,Selection, Patient,Selection, Research Subject,Selections, Research Subject,Subject Recruitment, Research,Subject Recruitments, Research,Subject Selection, Research,Subject Selections, Research,Subjects Selection,Subjects Selections,Treatment, Selection for,Treatments, Selection for,Volunteers Selection, Research
D024841 Fluoroquinolones A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Fluoroquinolone

Related Publications

Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
April 1992, The Journal of infectious diseases,
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
March 2021, Pathogens (Basel, Switzerland),
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
June 2011, Microbial drug resistance (Larchmont, N.Y.),
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
June 2009, Microbial drug resistance (Larchmont, N.Y.),
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
July 2017, Antimicrobial agents and chemotherapy,
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
February 2003, Emerging infectious diseases,
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
December 2002, Emerging infectious diseases,
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
October 2022, Microbiology spectrum,
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
February 2023, Antibiotics (Basel, Switzerland),
Leanne E Unicomb, and John Ferguson, and Russell J Stafford, and Rosie Ashbolt, and Martyn D Kirk, and Niels G Becker, and Mahomed S Patel, and Gwendolyn L Gilbert, and Mary Valcanis, and Lance Mickan, and
September 2010, Foodborne pathogens and disease,
Copied contents to your clipboard!